EGFR and prostate carcinoma: EGF-PE40 and EGF-PE24mut were able to specifically kill EGFR-expressing prostate cancer cells and were found to be more than 60- to 140,000-fold cytotoxic than the EGFR inhibitor erlotinib 9.